These Were The Five Best And Worst Performing Healthcare Stocks In September 202224/7 Wall Street • 10/17/22
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 ProgramGlobeNewsWire • 10/03/22
Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder ValueSeeking Alpha • 10/03/22
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBrGlobeNewsWire • 09/22/22
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical OfficerGlobeNewsWire • 09/15/22
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug AdministrationGlobeNewsWire • 09/06/22
Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 08/25/22
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/10/22
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business UpdateGlobeNewsWire • 08/10/22
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022GlobeNewsWire • 08/09/22
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPROPRNewsWire • 07/25/22
SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class Action - SPRONewsfile Corp • 07/25/22
Bronstein, Gewirtz & Grossman, LLC Reminds Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action Deadline and Last Few Hours to Actively ParticipateBusiness Wire • 07/25/22
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 07/25/22